Safety Study of a Liposomal Vaccine to Treat Malignant Melanoma
Phase 1
Completed
- Conditions
- Melanoma
- Interventions
- Biological: Lipovaxin-MM
- First Posted Date
- 2010-01-20
- Last Posted Date
- 2012-04-11
- Lead Sponsor
- Lipotek Pty Ltd
- Target Recruit Count
- 12
- Registration Number
- NCT01052142
- Locations
- 🇦🇺
Pain & Anaesthesia Research Clinic, Adelaide, South Australia, Australia
© Copyright 2025. All Rights Reserved by MedPath